Treatment of rheumatoid arthritis in the USA: Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate

James R. O’dell, Stanley B. Cohen, J. Carter Thorne, Joel Kremer

Research output: Contribution to journalArticle

Abstract

Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalOpen Access Rheumatology: Research and Reviews
Volume10
DOIs
StatePublished - Jan 1 2018

Fingerprint

Methotrexate
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Insurance Claim Review
Therapeutics

Keywords

  • Biologic
  • Claims
  • Methotrexate
  • Tumor necrosis factor

ASJC Scopus subject areas

  • Rheumatology

Cite this

Treatment of rheumatoid arthritis in the USA : Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate. / O’dell, James R.; Cohen, Stanley B.; Carter Thorne, J.; Kremer, Joel.

In: Open Access Rheumatology: Research and Reviews, Vol. 10, 01.01.2018, p. 97-101.

Research output: Contribution to journalArticle

@article{774421c81dd649d2ab3dd9e9eae2b63f,
title = "Treatment of rheumatoid arthritis in the USA: Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate",
abstract = "Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27{\%} of the 2009 cohort and 36{\%} of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1{\%} (2009 cohort) to 45.4{\%} (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA.",
keywords = "Biologic, Claims, Methotrexate, Tumor necrosis factor",
author = "O’dell, {James R.} and Cohen, {Stanley B.} and {Carter Thorne}, J. and Joel Kremer",
year = "2018",
month = "1",
day = "1",
doi = "10.2147/OARRR.S169152",
language = "English (US)",
volume = "10",
pages = "97--101",
journal = "Open Access Rheumatology: Research and Reviews",
issn = "1179-156X",
publisher = "Dove Medical Press Limited",

}

TY - JOUR

T1 - Treatment of rheumatoid arthritis in the USA

T2 - Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate

AU - O’dell, James R.

AU - Cohen, Stanley B.

AU - Carter Thorne, J.

AU - Kremer, Joel

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA.

AB - Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA.

KW - Biologic

KW - Claims

KW - Methotrexate

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=85064749103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064749103&partnerID=8YFLogxK

U2 - 10.2147/OARRR.S169152

DO - 10.2147/OARRR.S169152

M3 - Article

C2 - 30013407

AN - SCOPUS:85064749103

VL - 10

SP - 97

EP - 101

JO - Open Access Rheumatology: Research and Reviews

JF - Open Access Rheumatology: Research and Reviews

SN - 1179-156X

ER -